|
|
News Breaks | | | | November 18, 2012 | | 19:11 EDT |  | MNOV | MedicNova extends MN-166 patent position in Europe
MediciNova announced that it has received Notices of Allowance from the European Patent Office, EPO, for two pending patent applications. One covers the use of ibudilast, MN-166, in drug addiction and the other provides for ibudilast use to enhance opioid analgesia in acute pain settings. MN-166 is the company's lead drug development candidate for certain neurological conditions, including progressive multiple sclerosis, drug addiction, and pain. | |
|
News For MNOV From The Last 14 Days Check below for free stories on MNOV the last two weeks. |
|
|
| May 20, 2013 | | 16:29 EDT | | MNOV | Satomi Hajime reports 10% passive stake in MedicNova
 Subscribe for More Information | |
|
|
|
|
|
|
